By Stephen Nakrosis
The American depositary receipts of Ambrx Biopharma were trading higher after-hours on Tuesday following the news that shareholder Cormorant Asset Management L.P. boosted its stake in the company.
In a filing with the U.S. Securities and Exchange Commission, Ambrx said Cormorant recently bought 307,534 shares at an average…
Read the full article here